Obsidian to Present Updated Amsoki-cel Melanoma Data at SITC 2026
Obsidian Therapeutics will present updated Phase 1/2 data on amsoki-cel (OBX-115) in advanced melanoma at the SITC 2026 Annual Meeting, per BioSpace.
Topic
Phase 1 2 Trial
Topic
Topic
Topic
Obsidian Therapeutics will present updated Phase 1/2 data on amsoki-cel (OBX-115) in advanced melanoma at the SITC 2026 Annual Meeting, per BioSpace.